March 8, 2025

ITF Therapeutics Opens New Headquarters to Support Rare Disease Community

Community Resource Consultants Inc. (CRCI)

Community Resource Consultants Inc. (CRCI) is a Michigan-based organization specializing in trauma rehabilitation medical case management. With over 34 years of experience, CRCI is dedicated to empowering survivors of catastrophic auto accidents to regain control of their lives and achieve both physical and emotional well-being. Their team of Licensed Master Social Workers (LMSWs) and Registered Nurses (RNs) are experts in navigating the complexities of today’s healthcare system, ensuring that survivors receive the necessary services for their recovery and rehabilitation. CRCI’s core values include advocacy, people, knowledge, and dependability, reflecting their commitment to being leading advocates and facilitators of long-term collaborative care.

News Summary

ITF Therapeutics LLC has inaugurated its new U.S. headquarters in Concord, Massachusetts, dedicated to advancing treatment for Duchenne muscular dystrophy (DMD) and rare diseases. The 10,000 square foot facility aims to foster collaboration and accommodate growth with plans for up to 40 team members. The company’s new product, DUVYZAT™, which targets DMD, has received FDA approval, promising hope for families. With a focus on accessibility, patient advocacy, and innovative therapies, ITF aims to enhance care and support within the DMD community.

Exciting News for the DMD Community!

Big news on the horizon as ITF Therapeutics LLC has officially opened its new U.S. headquarters! Nestled in the heart of Concord, Massachusetts, this brand-new facility is set to make waves in the world of Duchenne muscular dystrophy (DMD) and other rare diseases. Mark your calendars for March 5, 2025—this date is sure to be a milestone for the community!

A Spacious New Home

The new headquarters, spanning a whopping 10,000 square feet, is located at 575 Virginia Road, Unit 201. With plenty of room to grow, this central hub will house corporate offices and meeting spaces designed specifically for the DMD community and other rare disease advocates.

Commitment to Growth

Under the leadership of President Matt Trudeau, ITF Therapeutics is on a fast track for growth. The company, which was established in January 2024, is dedicated to making a meaningful impact on the lives of those impacted by rare diseases. With plans to accommodate up to 40 team members, the headquarters fosters a collaborative working environment, all aimed at improving patient care.

Designed with Care

An important aspect of the new headquarters is its thoughtful design. ITF has worked closely with patient advocacy leaders to create a space that not only meets corporate needs but also enhances accessibility and comfort for all guests. This approach demonstrates a clear commitment to understanding the challenges faced by the DMD community.

Launching Life-Changing Therapies

ITF Therapeutics isn’t just stopping at opening an impressive headquarters. Their pioneering product, DUVYZAT™ (givinostat), received FDA approval and launched commercially on March 21, 2024. This innovative treatment targets DMD in patients aged six and older, marking a significant advancement in the fight against this debilitating disease.

Clinical Success

The FDA approval process for DUVYZAT was buttressed by the positive results found in the EPIDYS clinical trial. Findings from the trial showed a substantial improvement in physical mobility in patients compared to those who received a placebo. While the treatment does have some side effects, such as diarrhea, nausea, vomiting, and low platelet counts, it still represents hope for many families affected by DMD.

Supporting Families Every Step of the Way

In addition to providing transformative therapies, ITF Therapeutics is launching a comprehensive patient services program called ITF ARC. This program is designed to assist patients and their families with navigating the complex world of treatment access, insurance, and more—because no one should have to face this journey alone.

Leadership at the Helm

To ensure smooth operations and strategic growth, Erica L. Monaco has joined the ranks as the Chief Operating Officer. With her at the helm, ITF Therapeutics is well-equipped to tackle the challenges of rare diseases and to forge valuable partnerships within the community.

A Hub for Collaboration

As the headquarters opens its doors, the focus will remain on collaboration—particularly with patient advocacy groups. ITF Therapeutics aims to keep a finger on the pulse of the community’s needs to ensure that they are met within the company’s programs.

The establishment of this new headquarters in Concord symbolizes not just the growth of ITF Therapeutics, but also a renewed hope for the DMD community. Each step taken here is another leap towards making lives better—one patient at a time. Here’s to the exciting journey ahead!